Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$4.34
-4.8%
$6.15
$3.97
▼
$9.14
$525.86M2.14226,525 shs466,619 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$2.26
+1.8%
$2.48
$1.21
▼
$3.11
$418.98M0.242.63 million shs2.16 million shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$5.30
-3.6%
$6.75
$5.01
▼
$18.31
$447.11M0.691.89 million shs1.67 million shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$3.59
-7.7%
$4.00
$2.80
▼
$8.97
$129.45M0.6337,931 shs3.28 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-4.82%+1.88%-28.74%-38.18%-43.42%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
+1.80%-18.71%+4.15%-17.52%+71.21%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-3.64%-15.61%-24.39%-38.37%-64.67%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%+0.56%-10.70%-43.02%-50.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$4.34
-4.8%
$6.15
$3.97
▼
$9.14
$525.86M2.14226,525 shs466,619 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$2.26
+1.8%
$2.48
$1.21
▼
$3.11
$418.98M0.242.63 million shs2.16 million shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$5.30
-3.6%
$6.75
$5.01
▼
$18.31
$447.11M0.691.89 million shs1.67 million shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$3.59
-7.7%
$4.00
$2.80
▼
$8.97
$129.45M0.6337,931 shs3.28 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-4.82%+1.88%-28.74%-38.18%-43.42%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
+1.80%-18.71%+4.15%-17.52%+71.21%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-3.64%-15.61%-24.39%-38.37%-64.67%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%+0.56%-10.70%-43.02%-50.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
1.50
ReduceN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
2.83
Moderate Buy$6.13171.02% Upside
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2.82
Moderate Buy$19.67271.07% Upside
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SBTX, OVID, PHAT, and GYRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Lower Price TargetOverweight$14.00 ➝ $10.00
11/4/2026
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
Reiterated RatingSell (D-)
10/30/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Reiterated RatingBuy
10/30/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Reiterated RatingBuy
10/21/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Reiterated RatingBuy$15.00
10/15/2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
Reiterated RatingSell (D-)
10/15/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Reiterated RatingSell (D-)
10/15/2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
Initiated CoverageOutperform$5.00
10/15/2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
Initiated CoverageOutperform$5.00
10/14/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Reiterated RatingBuy$16.00
10/9/2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
Initiated CoverageOverweight
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$116.59M4.29$0.21 per share20.52$1.25 per share3.47
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$7.25M58.83N/AN/A$1.05 per share2.15
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$274.88M1.57N/AN/A($4.28) per share-1.24
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$5.03M-$0.20N/AN/AN/A-14.80%-7.39%-5.74%N/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$17.41M-$0.24N/AN/AN/AN/A-23.38%-20.76%N/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$221.25M-$1.03N/A4.77N/A-30.19%N/A-13.38%N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/AN/A-29.62%-28.20%N/A

Latest SBTX, OVID, PHAT, and GYRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.0848-$0.10-$0.0153-$0.10$0.03 millionN/A
11/5/2026Q3 2026
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-$0.15$0.04+$0.19$0.0030$28.40 million$32.93 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/A
4.32
3.89
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.05
11.97
11.97
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
1.76
1.72
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Institutional Ownership

CompanyInstitutional Ownership
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
23.99%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
72.24%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
618115.32 million104.37 millionOptionable
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
23188.73 million175.52 millionOptionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
37181.29 million73.71 millionOptionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

Silverback Therapeutics (NASDAQ:SBTX) Stock Falls 3.5% - Here's Why
Meet the Silverback, the Leader of the Troop
10 Fun Facts About Mountain Gorillas
ARS Pharmaceuticals Inc (SPRY)
Wild Isles
A look back at RNA Therapeutics – day one
SPRY ARS Pharmaceuticals, Inc.
FDA accepts ARS Pharma’s NDA for Neffy
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
SBTX Silverback Therapeutics, Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gyre Therapeutics stock logo

Gyre Therapeutics NASDAQ:GYRE

$4.34 -0.22 (-4.82%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$4.42 +0.08 (+1.73%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$2.26 +0.04 (+1.80%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$2.28 +0.03 (+1.11%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$5.30 -0.20 (-3.64%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$5.88 +0.58 (+11.02%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$3.59 -0.30 (-7.71%)
As of 11/16/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.